SS-31 (elamipretide)
Availability Off-label prescription
What it is
SS-31, known generically as elamipretide, is a four amino acid peptide that crosses into mitochondria and binds cardiolipin, a lipid unique to the inner mitochondrial membrane. Binding cardiolipin is meant to stabilise the machinery that makes cellular energy. In September 2025 it became the first mitochondria-targeted drug the FDA has ever approved, for one ultra-rare genetic disease.
Why people take it
Mitochondrial decline is one of the recognized hallmarks of aging, and SS-31 is the closest thing to a drug that acts on it directly. People reach for it wanting energy, endurance, and cellular resilience, and the new approval gives clinics something almost no other peptide has: a molecule a regulator reviewed and cleared.
How it's delivered
The approved product is a subcutaneous injection for patients with Barth syndrome weighing at least 30 kg. Some longevity clinics advertise compounded SS-31; it is not the approved product, and FDA's compounding rules do not allow copies of an approved drug to stand in for it. The approval does not extend to that use.
Where the evidence stands
Narrow success surrounded by expensive failures, which is the honest shape of it. The Barth syndrome approval came through the accelerated pathway from a 12-patient trial that missed its primary endpoints on walking distance and fatigue, with muscle-strength improvement appearing later in open-label follow-up. Elsewhere the record is worse: a phase 3 trial in primary mitochondrial myopathy failed to improve the six-minute walk or fatigue, and a trial in dry age-related macular degeneration missed as well. A randomized trial in 39 otherwise healthy older adults with low mitochondrial function tested muscle energy production and fatigue resistance. It found an immediate ATP-capacity signal, no significant fatigue-resistance improvement, and no persistent difference at day seven.
Estimated cost
- No verified reference price for compounded SS-31; FDA restricts compounding copies of an approved drug
- The approved rare-disease product is priced in a different bracket entirely
- Not covered by insurance for longevity use
Who offers it
We don't list providers for SS-31. Its approved form, Forzinity, is a specialty prescription for Barth syndrome.
Go deeper
The compound page, SS-31 in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Sleep, Recovery, and Energy, covers the mitochondrial group and what an approval for one rare disease does and does not prove.
Longevity.io is for educational purposes only and is not medical advice. Accelerated approval supported by a 12-patient trial and its open-label extension does not establish benefit for healthy adults. Confirm eligibility, product source, and pricing directly with any provider.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
